Back to search
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the tre…
To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved…
Up Until now, there is not well acepted treatment for relapsed/refractory (rr) acute myeloid luekemia (AML), which has low complete response and poor survival.…